Abstract 4634: Anthracycline based antibody-drug conjugates (ADCs) for the treatment of non-Hodgkin's lymphoma are effective in cell lines resistant to auristatin based ADCs.

Background. The homeostatic chemokine, CXCL13 (BLC, BCA-1), helps direct the recirculation of mature, resting B cells, which express its receptor, CXCR5. CXCL13/CXCR5 are expressed, and may play a role, in some non-AIDS-associated B cell tumors.Objective. To determine if CXCL13/CXCR5 are associated with AIDS-related non-Hodgkin's lymphoma (AIDS-NHL).Methods. Serum CXCL13 levels were measured by ELISA in 46 subjects who developed AIDS-NHL in the Multicenter AIDS Cohort Study and in controls. The expression or function of CXCL13 and CXCR5 was examined on primary AIDS-NHL specimens or AIDS-NHL cell lines.Results. Serum CXCL13 levels were significantly elevated in the AIDS-NHL group compared to controls. All primary AIDS-NHL specimens showed CXCR5 expression and most also showed CXCL13 expression. AIDS-NHL cell lines expressed CXCR5 and showed chemotaxis towards CXCL13.Conclusions. CXCL13/CXCR5 are expressed in AIDS-NHL and could potentially be involved in its biology. CXCL13 may have potential as a biomarker for AIDS-NHL.

Download Full-text

Somatic mutations and intraclonal variations in the rearranged Vk genes of B-non-Hodgkin's lymphoma cell lines

European Journal Of Haematology ◽

10.1111/j.1600-0609.1999.tb01766.x ◽

2009 ◽

Vol 63 (3) ◽

pp. 180-191 ◽

Cited By ~ 26

Author(s):

C. Gabay ◽

H. Ben-Bassat ◽

M. Schlesinger ◽

R. Laskov

Keyword(s):

Cell Lines ◽

Hodgkin’S Lymphoma ◽

Somatic Mutations ◽

Lymphoma Cell ◽

Hodgkin's Lymphoma ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/TCRγδ+) and DERL-7 (CD56+/CD3−/TCRγδ−), derived from a single patient with CD56+ non-Hodgkin's lymphoma

Leukemia ◽

10.1038/sj.leu.2402239 ◽

2001 ◽

Vol 15 (10) ◽

pp. 1641-1649 ◽

Cited By ~ 19

Author(s):

R Di Noto ◽

F Pane ◽

A Camera ◽

L Luciano ◽

M Barone ◽

...

Keyword(s):

Cell Lines ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Single Patient ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

CDC4 and NOTCH1 Mutations in Childhood T-Cell Acute Lymphoblastic Leukemia and T Cell Non-Hodgkin’s Lymphoma; a Japan Association of Childhood Leukemia Study Group.

Blood ◽

10.1182/blood.v110.11.2648.2648 ◽

2007 ◽

Vol 110 (11) ◽

pp. 2648-2648

Author(s):

Myoung-ja Park ◽

Tomohiko Taki ◽

Nobuhiro Suzuki ◽

Megumi Oda ◽

Keiko Yagi ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

T Cell ◽

Cell Lines ◽

Hodgkin’S Lymphoma ◽

Childhood Leukemia ◽

Lymphoblastic Leukemia ◽

Hodgkin's Lymphoma ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Notch1 Mutations

Abstract Risk-adapted therapy has resulted in a improvement of outcome in childhood acute lymphoblastic leukemia (ALL), however, T-cell ALL (T-ALL) have still relatively poor outcome compared to B-precursor ALL. Although activating mutations of the NOTCH1 gene have been reported in more than half of T-ALL, the prognostic significance of this finding has yet to be determined. CDC4 gene was isolated as a negative regulator of NOTCH1 and mutations were detected in T-ALL cell line and other cancers. We performed mutation analysis of the NOTCH1 and CDC4 gene in 14 T-ALL cell lines, 52 T-ALL and 17 T cell non-Hodgkin’s lymphoma (T-NHL) fresh samples. All children with T-ALL and T-NHL were treated on Japan Association of Childhood Leukemia Study (JACLS) ALL-97 and NHL-98 protocol after obtaining informed consent. Mutation detection was performed via PCR based denaturing HPLC followed by direct sequence.Mutations of the NOTCH1 were identified in 10 (71.4%) of 14 T-ALL cell lines, 16 (30.8%) of 52 T-ALL and 6 (35.3%) of 17 T-NHL fresh samples. Twelve mutations in heterodimerization domain (HD) and 12 mutations in PEST domain (PD) were found in 69 fresh samples. The incidence of the NOTCH1 mutation is less frequent than that of previous reports. We found CDC4 mutations in 12 (35.3%) of 52 T-ALL and 2 (11.8%) of 17 T-NHL fresh samples. One insertion mutation in exon 3 and 11 missense mutations were detected in CDC4 gene. Both NOTCH1 and CDC4 mutations were found in 7 patients. Interestingly, the NOTCH1 mutations were only observed in T-ALL and T-NHL patients without relapse, suggesting to be associated with favorable prognosis. However, CDC4 gene was found not to be associated with prognosis.

Download Full-text